Alkermes plc is a biopharmaceutical company focused on researching, developing, and commercializing pharmaceutical products to meet unmet medical needs across various therapeutic areas. Headquartered in Dublin, Ireland, it operates primarily in the United States and has a range of marketed products, including ARISTADA for schizophrenia and VIVITROL for alcohol and opioid dependence. The company also offers RISPERDAL CONSTA, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, and VUMERITY, which are used to treat conditions related to schizophrenia and multiple sclerosis. Alkermes is advancing its pipeline with additional drug candidates, such as ALKS 3831 for schizophrenia and ALKS 4230, an engineered protein aimed at enhancing immune responses in cancer treatment. The company collaborates with several partners, including Janssen Pharmaceutica and Biogen, to enhance its research and development capabilities. Alkermes combines its proprietary technologies to create innovative treatments, employing a comprehensive approach to address chronic diseases and disorders, thereby contributing to improved patient outcomes.
Rodin Therapeutics is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapeutics for cognitive disorders through the application of epigenetic insights. Founded in 2013 with backing from Atlas Venture and Johnson & Johnson Development Corporation, the company leverages advanced structural biology capabilities and a team experienced in central nervous system (CNS) drug development. Rodin's innovative approach centers on the modulation of histone deacetylase (HDAC) complexes to restore synaptic function and promote neuronal health in degenerative brain diseases. This strategy aims to address significant unmet medical needs in the treatment of neurological disorders. As of November 2019, Rodin operates as a subsidiary of Alkermes Inc.
Civitas Therapeutics is a biopharmaceutical company dedicated to developing therapies for pulmonary delivery. The company focuses on creating innovative treatments for central nervous system and respiratory disorders, with a particular emphasis on conditions such as multiple sclerosis and spinal cord injuries. Civitas Therapeutics aims to improve the health and quality of life for patients across the United States through its specialized drug delivery systems.
Enzytech
Acquisition in 1993
Enzytech is a health care company that develops an injectable drug system for multiple sclerosis patients. The company is baed in Cambridge, Massachusetts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.